Skip to main content

Advertisement

Table 5 Baseline predictive factors of CS less than 7.5 mg/day analyzed by multivariate analysis

From: Comparative study of corticosteroid monotherapy, and TNF inhibitors with or without corticosteroid in patients with refractory entero-Behcet’s disease

Variables Univariate logistic regression Multiple logistic regression
Wald P OR (95%CI) Wald P OR (95%CI)
Male, n (%) 0.9232 0.3365 0.53 (0.15–1.92)    
Age (years) 5.1680 0.0230 1.07 (1.01–1.14) 2.32 0.1135 1.06 (0.98–1.13)
Disease duration (entero-BD, months) 0.0186 0.8914 1.00 (0.99–1.01)    
Multiple ulceration, n (%) 3.6556 0.1559 0.26 (0.06–1.03)    
History of relapse, n (%) 0.3876 0.5336 0.53 (0.43–5.05)    
History of perforation, n (%) 0 1.0000 1.00 (0.18–5.63)    
History of surgery, n (%) 0.1704 0.6797 0.71 (0.14–3.64)    
Concomitant CS dose (mg/day) 1.0678 0.3014 0.98 (0.95–1.02)    
Concomitant colchicine use, n (%) 2.4121 0.1139 2.75 (0.767–9.86)    
Concomitant drugs use, n (%) (MTX, MS/SSZ, AZ) 1.2318 0.2556 2.40 (0.51–11.3)    
Concomitant MTX use, n (%) 11.811 0.0006 15.0 (3.20–70.4) 2.32 0.5228 2.38 (0.16–34.2)
TNF-i use, n (%) 15.033 < 0.0001 25.5 (4.96–131.1) 3.11 0.0778 10.8 (0.77–153.0)
DAIBD 2.3752 0.1233 0.98 (0.97–1.00)    
  1. Model χ2 test P < 0.0001. BD Behcet’s disease, CS corticosteroid, col colchicine, MS mesalazine, SSZ sulfasalazine, MTX methotrexate, AZ azathioprine, TNF-i TNF inhibitors, DAIBD disease activity index for intestinal Behcet’s disease